Alkermes, Inc.
Clinical trials sponsored by Alkermes, Inc., explained in plain language.
-
New narcolepsy drug shows promise in reducing sleep attacks and muscle collapse
Symptom relief CompletedThis study tested an experimental drug called ALKS 2680 in 92 adults with narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness (cataplexy). Participants stopped their usual medications and received either ALKS 2680 or a placebo for several w…
Phase: PHASE2 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated May 14, 2026 12:16 UTC
-
New pill aims to fight daytime sleepiness in narcolepsy
Symptom relief CompletedThis study tested a new tablet called ALKS 2680 in 93 adults with narcolepsy type 2, a condition that causes severe daytime sleepiness. Participants took either the study drug or a placebo to see if the drug could help them stay awake and feel less sleepy. The goal was to find th…
Phase: PHASE2 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated May 12, 2026 13:40 UTC